Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Commissariat &#xc0; L'&#xc9;nergie Atomique Et Aux &#xc9;nergies Alternatives

UniversitÉ Paris Descartes

Université De Paris—sud

Université Paris-Saclay

UniversitÉ De Paris

Inserm

Nathalie Cartier-Lacave

Nicole Deglon

Mickael Audrain

Philippe Hantraye

Jerome Braudeau

Patrick Aubourg

Jérôme Braudeau

Eloise Hudry

The present invention relates to a vector comprising a nucleic acid sequence that encodes the APP protein and/or the PS1 protein or variants thereof. The invention also relates to a method for inducing the Alzheimer's disease in an animal using the vector of the invention and to animal model having the Alzheimer's disease obtained by said method.

Alzheimer's disease animal model

The invention relates to a viral vector for treating Alzheimers disease, which vector comprises a cholesterol 24-hydroxylase (CYP46A1) encoding nucleic acid. In a preferred embodiment, the viral vector may be an Adeno-Associated-Virus (AAV) vector, preferably an AVV5 vector. The vector may be useful for the manufacture of a pharmaceutical composition for the treatment of Alzheimers disease in a subject, wherein the vector is to be administered directly into the brain of the subject or by intravenous or intrathecal injection.

CYP46A1 gene for the treatment of alzheimer's disease

Growing community of inventors

Le Kremlin Bicetre, France

Nathalie Cartier-Lacave